Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02080169
Other study ID # CMAqiluICU
Secondary ID
Status Recruiting
Phase Phase 4
First received February 25, 2014
Last updated March 5, 2014
Start date February 2014
Est. completion date December 2014

Study information

Verified date March 2014
Source Qilu Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ethics committee on Scientific Research of Shandong University of Qilu Hospital.
Study type Interventional

Clinical Trial Summary

It is well known that ICU patients need sedation. Now no ideal sedation drug existed and every sedation drug has its advantage and disadvantage,so combined sedation may use the advantage and avoid the disadvantage of the sedation drug according to the patients'condition. Until now, there is rare study about the combined sedation or sequenced sedation of different sedation drug.The purpose of the study is to explore the value of combined sedation with midazolam and dexmedetomidine compared to single drug sedation in ICU, so as to seek an ideal sedation protocol that could reduce the cost of treatment,obtain the appropriate sedation not under sedation or over sedation,reduce the incidence of delirium, reduce the adverse event of sedation.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. ICU patients needing sedation

2. 18 years or older

3. mechanically ventilated for less than 96 hours prior to start of study drug.

Exclusion Criteria:

1. Trauma and burn patients as admitting diagnosis.

2. Dialysis of all types.

3. Pregnant or lactation.

4. Neuromuscular blockade other than for intubation.

5. Epidural or spinal analgesia.

6. General anesthesia prior to or planned after the start of study drug infusion

7. Serious central nervous system pathology(acute stroke, uncontrolled seizures,severe dementia).

8. Acute hepatitis or severe liver disease (Child-Pugh class C).

9. Unstable angina or acute myocardial infarction.

10. Left ventricular ejection fraction less than 30%,heart rate less than 50/min. 11.Second or third degree heart block.

12.Allergy to the study drug. 13.Systolic blood pressure less than 90 mm Hg despite continuous infusions of 2 vasopressors before the start of study drug infusion.

14. Patients with renal insufficiency were randomized and treated; however, patients were discontinued if they required dialysis.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
midazolam
If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained. If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
Dexmedetomidine
If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained. If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
Fentanyl
Fentanyl is used as analgesic drug in order to obtain the VAS <3.

Locations

Country Name City State
China Department ICU, Shandong university affiliated Qilu Hospital. Jinan Shandong

Sponsors (2)

Lead Sponsor Collaborator
Qilu Hospital Chinese Medical Association

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The total time within target sedation level Sedation level with RASS score is recorded every 4 hours during sedation.
When target sedation was not obtained, sedation drug dosage changed and when adverse event needed to be treated, the sedation level is also recorded.
The adjustment of sedation drug is recorded.
From sedation drug is used to weaning from sedation up to 28 days. No
Secondary The dosage of sedation/analgesic drug Record the induced and maintained dosage of sedation/opioid analgesic drug. The total dosage of sedation/opioid analgesic drug. The added dosage of midazolam. From sedation/analgesic drug is used to weaning from sedation/analgesic up to 28 days. No
Secondary Duration of mechanical ventilation The duration of mechanical ventilation is recorded. From beginning to weaning from ventilation up to 28 days.. No
Secondary Economic outcome The cost of sedation drug used is recorded. The cost of mechanical ventilation is recorded. The cost of ICU residency is recorded. From admitted to ICU until ventilation and sedation stopped and participants discharged from ICU up to 28 days. No
Secondary Satisfactory of patients to ICU stay from admitted until discharged from ICU Evaluated the satisfactory of patients to ICU. Using scores including 0 to 10. 0 presents extremely dissatisfied and 10 presents extremely satisfied. Assessed at time of 1 week participants discharged from ICU. No
Secondary Delirium Delirium is evaluated when daily sedation interruption is done during sedation. Delirium incidence is recorded using CAM-ICU. Treatment of delirium is recorded including drug,dosage and method of administration. From sedation drug is used to weaning from sedation, up to 28 days. Yes
Secondary Vital signs Heart rate(HR),main arterial pressure(MAP),respiratory rate(RR),pulse saturate of oxygen(SPO2) are recorded every 4 hours. When sedation drug dosage changed and adverse events treated,the vital signs is also recorded.
Gas blood analysis index is recorded when the daily interruption is done and when the SPO2 is less 90% or 10% decrease than normal.
From sedation drug is used to weaning from sedation, up to 28 days. Yes
Secondary Duration of ICU stay Record when participants discharged form ICU. From date of admission until participants discharged from ICU up to 28 days. No
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT05891873 - Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Recruiting NCT06194474 - Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
Completed NCT03095417 - Improving the Recovery and Outcome Every Day After the ICU N/A
Completed NCT05395559 - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Not yet recruiting NCT04846023 - Pediatric Delirium Screening in the PICU Via EEG N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Withdrawn NCT02673450 - PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
Recruiting NCT03256500 - Transcranial Direct Current Stimulation for the Treatment of Delirium N/A
Completed NCT02890927 - Geriatric-CO-mAnagement for Cardiology Patients in the Hospital N/A
Not yet recruiting NCT02892968 - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients N/A
Recruiting NCT03165539 - Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
Completed NCT02518646 - DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models N/A
Completed NCT02554253 - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction Phase 2
Recruiting NCT02305589 - The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium N/A
Completed NCT02628925 - Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale N/A